AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

IMCR · NASDAQ · Biotechnology

Immunocore (ADR) (IMCR)

Develops ImmTAX-based immunotherapies and sells KIMMTRAK for eligible uveal melanoma patients.

$31.31

vs last close−1.11 (−3.41%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	54	56	71	75	80	84	94	98	104	77	107	116
Cost of revenue	2	0	0	2	0	0	1	1	1	3	0	1
Gross profit	52	56	70	74	80	84	93	97	103	75	106	115
	62	69	97	90	88	103	97	112	110	89	99	118
Research & development	33	36	57	51	53	61	56	69	71	58	61	74
	29	33	39	39	36	42	40	43	40	31	38	44
Selling & marketing	0	0	0	13	12	0	0	0	0	0	0	0
General & administrative	0	0	0	26	24	0	0	0	0	0	0	44
Operating income	−10	−14	−26	−16	−9	−19	−4	−15	−7	−15	7	−3
	12	−7	2	6	15	−5	10	5	7	3	6	2
Interest income	4	4	8	6	6	5	4	4	4	4	3	4
Interest expense	1	1	3	4	4	7	3	3	3	3	2	3
Other non-operating income	0	6	−6	−10	−18	−3	−13	−8	−11	−6	−8	−6
Income before tax	2	−20	−24	−10	6	−25	6	−10	0	−12	13	−1
Income tax expense	0	−5	0	1	−3	−1	1	1	0	11	0	0
Net income from continuing operations	2	−16	−24	−12	9	−24	5	−10	1	−22	13	−1
Net income	2	−16	−24	−12	9	−24	5	−10	1	−22	13	−1
EPS, basic	$0.02	−$0.32	−$0.49	−$0.23	$0.17	−$0.47	$0.10	−$0.21	$0.02	−$0.44	$0.26	−$0.02
EPS, diluted	$0.04	−$0.32	−$0.49	−$0.23	$0.17	−$0.47	$0.10	−$0.21	$0.02	−$0.44	$0.25	−$0.02
Weighted average shares, basic	54	49	50	50	50	50	50	50	50	50	51	51
Weighted average shares, diluted	54	49	50	50	53	50	52	50	50	50	53	51
EBITDA	−9	−19	−20	−5	11	−15	10	−6	4	−8	17	4
Depreciation & amortization	1	0	1	1	1	1	1	1	1	1	1	1
EBIT	−10	−19	−21	−6	10	−16	9	−7	3	−9	16	3